VERAXA Biotech has appointed Christoph Erkel, Ph.D., as its new chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will oversee the company’s innovative BiTAC® platform aimed at developing cancer therapies for solid tumors. He brings two decades of experience in antibody therapeutics and immuno-oncology from his prior role at MorphoSys AG. He succeeds Rick Austin, Ph.D., who will transition out of the role. VERAXA focuses on creating next-generation antibody-based therapeutics, leveraging advanced technologies and rigorous quality principles.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.newmediawire.com/news/veraxa-biotech-ag-vrxa-appoints-christoph-erkel-as-chief-scientific-officer-7087949
